Lahtela-Kakkonen M - Search Results

1

BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.

Kokkola T, Suuronen T, Pesonen M, Filippakopoulos P, Salminen A, Jarho EM, Lahtela-Kakkonen M. Kokkola T, et al. Chembiochem. 2015 Sep 21;16(14):1997-2001. doi: 10.1002/cbic.201500272. Epub 2015 Aug 13. Chembiochem. 2015. PMID: 26212199 Free PMC article.

2

Comparative and pharmacophore model for deacetylase SIRT1.

Huhtiniemi T, Wittekindt C, Laitinen T, Leppänen J, Salminen A, Poso A, Lahtela-Kakkonen M. Huhtiniemi T, et al. J Comput Aided Mol Des. 2006 Sep;20(9):589-99. doi: 10.1007/s10822-006-9084-9. Epub 2006 Nov 11. J Comput Aided Mol Des. 2006. PMID: 17103016

3

N,N'-Bisbenzylidenebenzene-1,4-diamines and N,N'-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors.

Kiviranta PH, Leppänen J, Kyrylenko S, Salo HS, Lahtela-Kakkonen M, Tervo AJ, Wittekindt C, Suuronen T, Kuusisto E, Järvinen T, Salminen A, Poso A, Wallén EA. Kiviranta PH, et al. J Med Chem. 2006 Dec 28;49(26):7907-11. doi: 10.1021/jm060566j. J Med Chem. 2006. PMID: 17181175

4

Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors.

Huhtiniemi T, Suuronen T, Rinne VM, Wittekindt C, Lahtela-Kakkonen M, Jarho E, Wallén EA, Salminen A, Poso A, Leppänen J. Huhtiniemi T, et al. J Med Chem. 2008 Aug 14;51(15):4377-80. doi: 10.1021/jm800639h. Epub 2008 Jul 22. J Med Chem. 2008. PMID: 18642893

5

Characterization of the binding properties of SIRT2 inhibitors with a N-(3-phenylpropenoyl)-glycine tryptamide backbone.

Kiviranta PH, Salo HS, Leppänen J, Rinne VM, Kyrylenko S, Kuusisto E, Suuronen T, Salminen A, Poso A, Lahtela-Kakkonen M, Wallén EA. Kiviranta PH, et al. Bioorg Med Chem. 2008 Sep 1;16(17):8054-62. doi: 10.1016/j.bmc.2008.07.059. Epub 2008 Jul 24. Bioorg Med Chem. 2008. PMID: 18701307

6

N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2.

Huhtiniemi T, Suuronen T, Lahtela-Kakkonen M, Bruijn T, Jääskeläinen S, Poso A, Salminen A, Leppänen J, Jarho E. Huhtiniemi T, et al. Bioorg Med Chem. 2010 Aug 1;18(15):5616-25. doi: 10.1016/j.bmc.2010.06.035. Epub 2010 Jun 17. Bioorg Med Chem. 2010. PMID: 20630764

7

Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2.

Huhtiniemi T, Salo HS, Suuronen T, Poso A, Salminen A, Leppänen J, Jarho E, Lahtela-Kakkonen M. Huhtiniemi T, et al. J Med Chem. 2011 Oct 13;54(19):6456-68. doi: 10.1021/jm200590k. Epub 2011 Sep 7. J Med Chem. 2011. PMID: 21895016

8

Synthesis and evaluation of substituted chroman-4-one and chromone derivatives as sirtuin 2-selective inhibitors.

Fridén-Saxin M, Seifert T, Landergren MR, Suuronen T, Lahtela-Kakkonen M, Jarho EM, Luthman K. Fridén-Saxin M, et al. J Med Chem. 2012 Aug 23;55(16):7104-13. doi: 10.1021/jm3005288. Epub 2012 Aug 7. J Med Chem. 2012. PMID: 22746324 Free PMC article.

9

Identification of novel SIRT3 inhibitor scaffolds by virtual screening.

Salo HS, Laitinen T, Poso A, Jarho E, Lahtela-Kakkonen M. Salo HS, et al. Bioorg Med Chem Lett. 2013 May 15;23(10):2990-5. doi: 10.1016/j.bmcl.2013.03.033. Epub 2013 Mar 16. Bioorg Med Chem Lett. 2013. PMID: 23562596

10

Screen of pseudopeptidic inhibitors of human sirtuins 1-3: two lead compounds with antiproliferative effects in cancer cells.

Mellini P, Kokkola T, Suuronen T, Salo HS, Tolvanen L, Mai A, Lahtela-Kakkonen M, Jarho EM. Mellini P, et al. J Med Chem. 2013 Sep 12;56(17):6681-95. doi: 10.1021/jm400438k. Epub 2013 Aug 22. J Med Chem. 2013. PMID: 23927550

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page